Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

Company Calls Off Inhaled Remdesivir Program

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.

earnings report
Gilead reported in its second quarter 2021 earnings that its HIV business was showing signs of recovery from its pandemic-induced decline • Source: Shutterstock

For yet another quarter, Gilead Sciences, Inc.’s COVID-19 antiviral drug played a leading role in driving the company’s revenues. But now there are signs of a shift as Veklury (remdesivir) saw a quarter-over-quarter decline in sales, while other areas of Gilead’s antivirals business – especially HIV and hepatitis C (HCV) – showed signs of recovery. Still, the HIV treatment market’s recovery in the US has not happened as quickly as the company hoped.

Foster City, CA-based Gilead’s overall revenues were $6.2bn for the second quarter, a 21% increase over Q2 2020. (See chart...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.